SynthesisClinical rheumatology2026
Prevalence of interstitial lung disease in patients with psoriatic arthritis: a systematic review and meta-analysis.
Synthesis in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterstitial lung disease (ILD) is not classically considered an extra-articular manifestation of psoriatic arthritis (PsA). However, emerging evidence suggests that pulmonary involvement may be more common than previously recognized. The prevalence of ILD in PsA remains poorly defined.
objectivesTo estimate the pooled prevalence of ILD among patients with PsA and to evaluate associated risk factors and comparative risk with other populations.
methodsWe conducted a systematic review and meta-analysis registered in PROSPERO. MEDLINE (PubMed), EMBASE (Scopus), and the Cochrane Library were searched from inception to January 2026. Observational studies reporting ILD prevalence in PsA were included. Random-effects models with logit-transformed proportions were used to pool prevalence estimates. Subgroup analyses were performed based on ILD diagnostic method.
resultsSix studies comprising 14,272 patients with PsA were included. The pooled prevalence of ILD was 3% (95% confidence interval [CI]: 1%-7%; I
conclusionsInterstitial lung disease affects a meaningful proportion of patients with psoriatic arthritis, particularly when imaging-based diagnostic methods are used. ILD may be underrecognized in routine clinical practice. Increased awareness, standardized diagnostic approaches, and prospective studies are needed to define optimal screening and management strategies for ILD in PsA. PROSPERO registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261278657 Key Points • Interstitial lung disease may be an underrecognized comorbidity in psoriatic arthritis. • The prevalence appears higher when imaging-based diagnostic methods are used.
Indexed as
Identifiers
41832319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.